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OLIGODENDROGLIOMA IN A PATIENT WITH AIDS: CASE REPORT AND
REVIEW OF THE LITERATURE
Marcelo E. CORTI(1), Claudio YAMPOLSKY(1), Humberto METTA(1), Mario VALERGA(1), Gustavo SEVLEVER(2) & Andrés CAPIZZANO(3)
SUMMARY
In the last years, new techniques of neuroimages and histopathological methods have been added to the management of cerebral
mass lesions in patients with AIDS. Stereotactic biopsy is necessary when after 14 days of empirical treatment for Toxoplasma gondii
encephalitis there is no clinical or neuroradiologic improvement. We report a woman with AIDS who developed a single focal brain
lesion on the right frontal lobe. She presented a long history of headache and seizures. After two weeks of empirical treatment for
toxoplasma encephalitis without response, a magnetic resonance image with spectroscopy was performed and showed a tumoral
pattern with a choline peak, diminished of N-acetyl-aspartate and presence of lactate. A stereotactic biopsy was performed.
Histopathological diagnosis was a diffuse oligodendroglioma type A. A microsurgical resection of the tumor was carried out and
antiretroviral treatment was started. To date she is in good clinical condition, with undetectable plasma viral load and CD4 T cell
count > 200 cell/uL.
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INTRODUCTION
Primary central nervous system lymphoma (PCNSL) is the most
frequent neoplasm diagnosis to be considered in patients infected with
the human immunodeficiency virus type-1 (HIV-1) and focal brain
lesions. However, malignant gliomas or other cerebral tumors may often
occur in patients with the acquired immunodeficiency syndrome (AIDS)
and have been reported in these patients in several series11. We report a
case of oligodendroglioma in an AIDS patient and review of the literature.
CASE REPORT
A 31-year old woman presented a generalized seizure and was
referred to our Unit of Infectious Diseases. She had a history of
intravenous drug addiction and a diagnosis of AIDS in 1988. She had
experienced intermittent headaches and some seizure episodes for 18
months without diagnosis. On physical examination she was alert and
had no neurological deficit or papilledema. Serology for toxoplasmosis
was IgM negative and IgG 1/64. The CD4 T cell count was 42 cells/uL.
A brain magnetic resonance imaging (MRI) was performed and
demonstrated a solitary intracerebral mass lesion with hypointense signal
in T1 and hypertense signal in T2 weighted images, involving the right
frontal lobe and the insula with moderate peripheral edema and without
enhancement after gadolinium administration. A presumptive clinical
and radiological diagnosis of toxoplasma encephalitis (TE) was made
and empirical antitoxoplasma treatment (pirimetamine, sulfadiazine and
leucovorine) was initiated. After 2 weeks of empirical treatment, she
developed a new seizure episode and headache, and a MRI spectroscopy
was performed. The lesion failed to show any change and spectroscopy
demonstrated a choline peak with diminished N-acetyl aspartate (NAA)
and presence of lactic acid. Spectroscopic and radiological findings and
his history of HIV/AIDS disease suggested a primary central nervous
system lymphoma (PCNSL) and a stereotactic brain biopsy was
performed. The patient’s recovery following the biopsy procedure was
uneventful. Histopathological examination of the specimen disclosed a
monomorphous glioma of moderate cellularity with uniform round nuclei
and clear cytoplasm. Small gemistocytes were also observed. Tumor
cells showed a trend to infiltrate the non-tumoral brain. Histopathologic
diagnosis was diffuse oligodendroglioma type A (Fig. 1, 2).
Antiretroviral therapy was started and four months after diagnosis,
a microsurgical resection of the tumor through a pterional craniotomy
was carried out. The patient had an uneventful postoperative course, and
three days after surgery she was discharged.
To date, she remains on highly active antiretroviral therapy (HAART)
based on zidovudine plus lamivudine plus efavirenz with a good clinical,
immunological and virological response. Twenty eight months after the
onset of neurological symptoms, is still in good clinical condition and
without neurological deficit. The CD4 T cell count is > 200 cell/uL and
the plasma viral load was undetectable.
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DISCUSSION
Neurological involvement in patients with AIDS is common.
Approximately 40% to 60% of patients with AIDS develop some
neurological disorder at some stage of the disease. Glioma comprise a
collection of tumors arising from their glial precursors within the central
nervous system (CNS). The malignant glioma is the most common
primary brain neoplasm, but it is not generally included in the differential
diagnosis of enhancing lesions of the CNS in patients with the acquired
immunodeficiency syndrome. Three histological types of diffuse
infiltrative tumors are recognized by the World Health Organization
(WHO) classification of gliomas: astrocytomas, oligodendrogliomas and
oligoastrocytomas10. These tumors are further classified by subtypes and
by histological grading as either low grade (WHO grade II) or anaplastic
(WHO grade III). Grade of tumor appears to be the most significant
prognosticator1.
The diagnosis of oligodendrogliomas has been based in typical
microscopic features5. Moreover, a characteristic gen alteration, allelic
loss of chromosomes 1p and 19q, may help to identify an
oligodendrogliomal component. The concurrent loss of chromosomal
arms 1p and 19q appears to identify a subgroup with a more favorable
prognosis and a greater response to postoperative treatment4.
Histologically distinguishing between pure oligodendrogliomas from
other gliomas is very important in determining if chemotherapy may be
an effective treatment2. Resorting to morphological criteria and other
common features, the prevalence of the oligodendroglioma has been
estimated to range from 5% to 7% of all glial tumors5. However, several
recent studies of these tumors have focused on the significance of
quantitatively assessing tumor proliferation using bromodeoxyuridine,
MIB-1/Ki-67 and proliferating cell nuclear antigen7,8. In this context,
and using expanded criteria, it is not unlikely that the oligodendrogliomas
(or mixed tumor) are underdiagnosed, so that it has been suggested that
the oligodendrogliomas may represent 25% to 33% of all glial tumors8,9.
Although PCNSL and TE continue to be the most common
intracranial lesions in HIV-infected patients, other pathologic entities
should be included in the differential diagnosis of enhancing lesions of
the CNS in patients with AIDS.
However, the low incidence of this association reported in the medical
literature could be a sign of the nonexistence of a pathogenesis relation
between AIDS and the development of gliomas.
Up to 1999, only 28 HIV-infected patients with primary brain tumors
other than PCNSL have been reported in the literature. In 14 patients of
this series, tumor was diagnosed a median of 2 years after the diagnosis
of HIV. In our patient, the time interval between HIV diagnosis and
tumor diagnosis was 18 months.
In 1999, BLUMENTHAL et al.3 published another report on eight
patients; four of them had a diagnosis of AIDS as our patient and five
were glioblastoma multiforme, the most aggressive and the most common
of all gliomas12. The median of CD4 T cell count of Blumenthal’s series
was 169 cell/uL3; our patient had less than 50 CD4 T cell/uL at the time
of neoplasm diagnosis. However, there was no relation between higher
or lower grade tumor histology based on CD4 count; neither was there
any association between CD4 count and tumor outcome3.
The most common location of these tumors is in the frontal lobes
(40% to 70%), in the white matter and with little or no surrounding
edema. Our patient had a right frontal lesion, without contrast
enhancement and presenting perilesional edema of the white matter. Less
frequently, the oligodendroglioma may involve other parts of the brain,
the brainstem, cerebellum, third ventricle and the spinal cord. The
oligodendroglioma grows slowly and the interval between the onset of
symptoms and the diagnosis is protracted; in this specific case, the interval
was 18 months.
As in our patient, the first symptom in over half of the patients is a
focal or generalized seizure and 70% of patients with oligodendroglioma
develop seizures during the evolution of the disease. Only one third
Fig. 1 - Photomicrograph, haematoxylin-eosin stain x 400, demonstrates moderate cellularity,
and a perivascular infiltrate with atypical neoplastic oligodendrocytes with uniform round
nucleus and perinuclear halo.
Fig. 2 - Photomicrograph, haematoxylin-floxin stain x 250, showed neoplastic
oligodendrocytes and small gemistocytes.
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exhibit focal cerebral signs and about half of all cases have increased
intracranial pressure by the time surgery is performed. Gliomas may be
included in the differential diagnosis of cerebral mass lesions in AIDS
patients. Early stereotactic biopsy is needed to establish the diagnosis
and is recommended by many authors6. A correct diagnosis has a
significant impact on patient survival and a poor outcome is related with
a delay in establishing the correct diagnosis13. Surgical excision is the
treatment of choice for these tumors; however, a number of patients
have recurrences within a few months after surgery. We conclude that a
routine histopathological diagnosis of focal mass lesions in patients with
AIDS and a poor response after 2 weeks of empirical antitoxoplasma
treatment might disclose gliomas to be more common than currently
recognized14.
RESUMEN
Oligodendroglioma en un paciente con sida: reporte de caso y
revisión de la literatura
En los últimos años, las nuevas técnicas de neuroimágenes y diversos
métodos de diagnóstico histopatológico se han agregado al manejo clínico
de las lesiones de masa cerebral ocupante en los pacientes con sida. La
biopsia estereotáxica es necesaria cuando, luego de dos semanas de
tratamiento empírico para toxoplasmosis cerebral, no se comprueba
mejoría clínica ni neurorradiológica. Presentamos una paciente con sida
que desarrolló una lesión cerebral a nivel del lóbulo frontal derecho.
Como antecedente refirió una larga historia de cefalea y convulsiones.
La resonancia nuclear magnética con espectroscopia de voxel único
ubicado a nivel de la lesión mostró un patrón de lesión tumoral con pico
de colina, déficit de N-acetil-aspartato y presencia de ácido láctico. La
biopsia estereotáxica y el estudio histopatológico permitieron arribar al
diagnóstico de oligodendroglioma difuso de tipo A. Se le efectuó
resección por microcirugía y tratamiento antirretroviral de alta eficacia.
Actualmente la paciente se encuentra en buen estado clínico, con carga
viral indetectable y recuento de linfocitos T CD4 + > de 200 cél/uL.
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